Effect of pentoxifylline versus vitamin C on clinical signs in patients with pigmented purpuric eruption

Effect of pentoxifylline versus vitamin C on clinical signs in patients with pigmented purpuric eruption: a double-blind randomized clinical trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT201503129014N58

Enrollment

Registered

2015-03-17

Start date

2015-04-04

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pigmented purpuric dermatosis. Pigmented purpuric dermatosis

Interventions

Intervention 1: oral pentoxifylline 400 mg daily for 8 weeks. Intervention 2: oral vitamin C 500 mg daily for 8 weeks.

Treatment - Drugs

Placebo

oral pentoxifylline 400 mg daily for 8 weeks

oral vitamin C 500 mg daily for 8 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria: (a) affecting with pigmented purpuric eruption. Exclusion criteria: (a) Coronary artery disease; (b) history of myocardial infarction; (c) renal failure; (d) pregnancy.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Measuring the skin lesions. Timepoint: before intervention and then every 2 weeks for 8 weeks. Method of measurement: through physical examination and photography.	—

Secondary

Measure	Time frame
Nothing. Timepoint: Nothing. Method of measurement: Nothing.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Ali Asghar Rezanejad

Farshchian Hospital

dr.rezanejad@chmail.ir+98 81 3827 4184

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026